Current research into retatrutide peptide reveal significant possibility for treating excess body and non-insulin dependent disease. The compound, a dual stimulator of GLP-1 and GIP, appears to offer improved body mass and glycemic management versus existing treatments. Further research efforts are required to fully evaluate its safety record and e